Shruti Bhat PhD, MBA, Operations Excellence Expert
  • Home
  • About Shruti
  • Books
  • Insights
  • Operational Excellence
  • Research
    • Innovation Management
    • Leading Research and Development
    • Developer's Diary
  • Case Studies
  • Tools
    • Whitepapers
    • Articles >
      • Business Transformation
      • Process Improvement
      • Business Continuity
      • Change Management
      • Digital Transformation
      • Quality Improvement
    • Checklists and Templates
    • Free eBook
    • Videos
  • Blog
  • Engage Shruti
    • Consulting >
      • Operational Excellence Consulting
      • Business Transformation Consulting
      • Innovation Management Consulting
    • Workshops
  • Contact

Strategies To Prevent Heart Attacks In Type 2 Diabetes Patients May Be Ineffective, Harmful.

3/22/2010

0 Comments

 
Picture
Dr.Shruti Bhat, an Expert in Pharmaceutical industry, brings to you some highlights from current pharma and clinical research news, views and data. 

The New York Times reported  that, according to studies presented at the American College of Cardiology meeting and to be published online March 18 by the New England Journal of Medicine, "aggressive treatment strategies doctors had expected would prevent heart attacks among people with type 2 diabetes and some who are the verge of developing it have proved to be ineffective or even harmful." Still, some experts, such as Dr. Daniel Einhorn, said that the results of these studies "would not necessarily dissuade him from taking such intensive measures with individual patients." He conceded, however, "It's hard to make a case for a public health recommendation. 

The Wall Street Journal  reported that the ACCORD study of a subset of 5,518 patients found that treating hypertension to levels currently lower than recommended in practice does not lower the risk of stroke, heart attack, or death in type 2 diabetes patients. Moreover, researchers also found that Abbott's drug TriCor (fenofibrate), even though it did lower triglyceride levels, did not stop patients from having strokes and heart attacks. In another study, the drug Starlix (nateglinide) did not stop patients at high risk for type 2 diabetes from eventually developing the condition.  

The ACCORD study findings "provoked a sharp response from Abbott vice president Eugene Sun, who said in a statement that" in patients with "abnormally high triglycerides or low levels of good cholesterol," combining "fenofibrate and simvastatin reduced heart attacks, strokes, and deaths by 31% over simvastatin alone." Meanwhile, cardiologist Steven Nissen, MD, of the Cleveland Clinic, pointed out the risk of a "higher incidence of kidney failure and other serious side effects" revealed when "doctors examined the benefits of intensive blood pressure lowering in diabetic patients and found that it failed to reduce deaths, heart attacks, and strokes taken together." 

A decade ago, the federal government launched the three-part study to see whether intensely lowering blood sugar, blood pressure, or fats in the blood would reduce heart attacks and strokes in diabetics. The first piece of the study -- about blood sugar -- was stopped two years ago, when researchers saw more instead of less risk with that approach." As for what to do now, cardiologist Clyde Yancy and other experts advised diabetic patients to "focus on healthy diets and lifestyles, and take tried-and-true medicines that doctors recommend now to control health risks."  

 One report focuses particularly on TriCor's failure "to cut the risk of heart attacks, strokes and cardiac deaths in diabetics." In a related piece, Bloomberg News  reported  that "Novartis AG's top blood pressure pill Diovan (valsartan) failed to prevent heart attacks, strokes or deaths in high-risk patients, while its diabetes drug Starlix didn't protect them from developing heart disease or diabetes." HealthDay  3rd March issue, also focused on the Diovan and Starlix study conclusions.  

In an editorial accompanying the studies, the Los Angeles Times "Booster Shots" blog reported that "Dr. David Nathan, of Massachusetts General Hospital, wrote that the 'prevention of diabetes remains a critical public health priority, but for now we should steer away from" Diovan and Starlix, "'and use effective lifestyle interventions" or metformin."  

Tthe findings come from the huge National Heart, Lung, and Blood Institute-funded Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial which, overall, involved more than 10,000 patients with type 2 diabetes at risk for heart disease. 

FDA To Review ACCORD Study. 

In a related story, The FDA said it will conduct a full review of findings from a study which concluded that neither aggressive lipid-lowering therapy nor tight blood pressure control reduced cardiovascular events in persons with diabetes." The study found the "addition of fenofibrate" to statin therapy "did not reduce cardiovascular events." MedPage Today noted that an FDA "spokesperson said the agency planned to include a review of the labeling and indications for fenofibric acid (Trilipix). It should, however, be noted that the trial used fenofibrate (TriCor)."  

Disclaimer- The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances. 

More at http://www.pharm-education.com/2010/03/strategies-to-prevent-heart-attacks-in.html 

Http://www.drshrutibhat.comExpert at leading Pharmaceutical R&D.
Translates innovative concepts to PROFITS.
Do you have questions for the author?

0 Comments

Your comment will be posted after it is approved.


Leave a Reply.

    Shruti Bhat, global leader in business turnaround, operational excellence and continuous improvement
    To contact Dr. Shruti Bhat text or WhatsApp at 1.403.969.6219

    New Book Released!

    Revolutionizing Industries with Lean Six Sigma

    Shruti's YouTube Channel ...

    Picture

    Blog Categories

    All
    3D Printing
    Agile
    Artificial Intelligence
    Automation
    Biotechnology
    Books
    Business Continuity
    Business Turnaround
    Case Studies
    Change Management
    Checklists
    Chemical Industry
    Continuous Improvement
    Design Thinking
    Digitalization
    Drug Delivery
    External News Links
    Hall Of Fame
    Healthcare
    Hoshin Kanri
    HR Development
    Innovation
    Insights
    ISO
    Just In Time
    Kaizen
    Leadership
    LEAN
    Lean Six Sigma
    Life Sciences
    Machine Learning
    Manufacturing
    Medical Devices
    Mistake Proofing
    Motivational Cards
    MSMEs
    Nanotechnology
    Operational Excellence
    Packaging
    Patents
    Personal Products
    Process Improvement
    Product Development
    Productivity Increase
    QbD
    Quality Management
    R&D Leadership
    Robotics
    Service Industry
    Six Sigma
    Strategy
    Supply Chain Logistics
    Telecom Industry
    Templates
    TQM
    Videos
    Voice Of Customer
    Whitepaper
    Workshops

    Shruti's books...

    Picture
    top ten strategic decision-making tools for operational excellence
    shruti bhat, business process management, continuous improvement
    kaizen for pharmaceutcials, medical devices and biotech industry book by Dr Shruti Bhat
    Book on Continuous improvement tools by Dr Shruti Bhat
    kaizen for leaders, continuous process improvement tool to increase profit and organizational excellence by shruti bhat
    kaizen, shruti bhat, continuous improvement, quality, operations management
    how to lead a successful business transformation
    leading organizations through crisis
    emotional intelligence
    how to overcome challenges of creating effective teams
    modular kaizen Vs Blitz kaizen
    How to increase employee engagement as a new boss

Connect with Dr. Shruti Bhat at- ​Twitter, YouTube, LinkedIn​

© Copyright 1992- 2025 Dr. Shruti Bhat ALL RIGHTS RESERVED.
See Terms and Conditions for details on this site usage.
Subscribe to Operational Excellence Academy YouTube Channel
​Subscribe to Operational Excellence Academy YouTube Channel
SHRUTI BHAT, CONTACT
Click to connect.
Created by Macro2Micro Media